Acorda Therapeutics, Inc. (NASDAQ:ACOR) This autumn 2022 Earnings Convention Name March 9, 2023 8:30 AM ET
Firm Members
Tierney Saccavino – Investor Relations
Ron Cohen – President and Chief Govt Officer
Michael Gesser – Chief Monetary Officer
Convention Name Members
Boobalan Pachaiyappan – H.C. Wainwright
Operator
Welcome to the Acorda Therapeutics Fourth Quarter and 12 months-Finish 2022 Monetary and Enterprise Replace. [Operator Instructions] Please be suggested that this name is being recorded on the firm’s request.
I’ll now introduce your host for as we speak’s name, Tierney Saccavino, at Acorda. Tierney, please go forward.
Tierney Saccavino
Thanks, Emily, and good morning, everybody. So earlier than we start, let me remind you that our presentation will comprise forward-looking statements. Detailed disclosures may be present in our SEC filings, that are public, and we encourage you to seek advice from these filings. At the moment, in the course of the Q&A, we are going to first take calls from our analysts, after which we are going to take questions that different traders have written in once they have registered for the decision.
I will now move the decision over to our CEO, Ron Cohen. Ron?
Ron Cohen
Thanks, Tierney. Good morning, everybody. Diving proper in, in 2022, we achieved a stream of enterprise successes, significantly within the latter 3 quarters of the yr that each one elevated shareholder worth. Regardless of an unusually difficult first quarter that severely impacted INBRIJA gross sales, which we consider was associated to the COVID Omicron surge. The quarter delivered sturdy monetary and operational efficiency. We met our monetary steerage for AMPYRA and INBRIJA U.S. web gross sales and likewise for working bills though we weren’t money circulation impartial in This autumn. We considerably lowered the trajectory of our money burn and we count on to be money circulation impartial or constructive for 2023.
Extra successes included closing an settlement with Biopas, to commercialize INBRIJA within the 9 largest Latin American nations. The launch of INBRIJA by Esteve in Germany and the licensing of our medical stage asset, Nepicastat to Asieris for $500,000 upfront plus as much as $7 million in regulatory milestones plus royalties on gross sales of commercialized merchandise. We obtained an award of $18.3 million in our AMPYRA arbitration with Alkermes that additionally resulted in a marked discount of our value of products going ahead. We count on to avoid wasting $10 million to $12 million in these prices in 2023 alone.
And we renegotiated our agreements with Catalyst, which we count on to considerably scale back our value of products for INBRIJA going ahead. And as well as, we obtained a waiver of our $27 million in Finland loans. And thus far within the new yr, we have obtained an extension from NASDAQ to June 20, 2023, to deliver the corporate’s share value again into compliance with NASDAQ itemizing necessities, thus avoiding having to implement a reverse inventory cut up. And we simply introduced that Esteve has additionally launched in INBRIJA in February in Spain.
So shifting to INBRIJA. INBRIJA, U.S. web gross sales for the total yr 2022 have been $28 million. That was a 5.6% lower from 2021 and fourth quarter U.S. web gross sales have been $9 million, a 13.1% lower over This autumn 2021.
However a 146% enhance over the primary quarter of 2022, and I will focus on this in additional element within the subsequent 3 slides. So that you see right here the sample of web gross sales every quarter since launch. General, the development repeats itself every year. Gross sales at all times dip within the first quarter on account of insurance coverage deductibles resetting and This autumn buy-in by the specialty pharmacies after which gross sales elevated steadily in the course of the yr. Nonetheless, gross sales dropped much more in Q1 2022 than within the prior first quarters of the launch. And we consider that this extreme drop was primarily associated to the COVID Omicron surge that occurred in finish of This autumn and thru Q1 2022, that was by far the biggest surge of the pandemic.
Nonetheless, gross sales recovered very nicely in the course of the yr.
And as I famous, This autumn gross sales have been 146% larger than Q1. We noticed the same sample on this subsequent slide in whole prescriptions or TRx, which dropped by an outsized 27% in Q1 2022 after which recovered a lot of that misplaced floor over the yr.
And right here you see cartons allotted to sufferers, which is essentially the most correct measure of true demand. This additionally adopted the same sample. You see a minimal drop in 2021 in Q1 2021 versus This autumn 2020. However a 25% drop in Q1 2022 versus This autumn 2021 .
And once more, we progressively recovered most of that misplaced floor in the course of the yr. For the primary 2 months of 2023, we’re operating considerably forward of 2022 comparable interval in dispenses thus far. And we’re additionally inspired that new prescription request varieties for January and February are considerably increased than the comparable interval final yr.
On this subsequent slide, primarily based on these encouraging developments in addition to responses to the brand new packages that we have been implementing, we consider we are going to proceed to develop the INBRIJA model within the U.S. and ex U.S. in 2023.
And we’re offering U.S. web gross sales steerage of $38 million to $48 million. INBRIJA at the moment has 67% of on-demand remedy marketplace for Parkinson’s illness. However fewer than 2% of the about 380,000 folks with Parkinson’s who might qualify are at the moment taking any of the on-demand remedies and that provides us a major alternative to develop that market, significantly now that sufferers and physicians are shifting previous COVID.
Simply to evaluate a number of the new packages that we have been implementing. Our new model marketing campaign for INBRIJA is concentrated on educating well being care professionals, folks with Parkinson’s and their care companions in regards to the emotional influence of OFF durations on the lives of each folks with Parkinson’s and their care companions. That is vital, we have realized from our expertise thus far out there that that is one thing that’s extensively missed amongst well being care professionals who deal with Parkinson’s illness.
They perceive in regards to the medical elements of OFF durations, however they do not — a lot of them do not absolutely grasp the influence on their sufferers. And simply to present you an illustration or a few illustrations as a result of we speak to plenty of sufferers on the market. In case you contemplate somebody whose main exercise, for example, is golf. And that is their main social exercise, it is their main train. And that is essential for folks with Parkinson’s to remain energetic, to train, to be social as a result of it may be an isolating illness.
And final couple of instances they went {golfing} on the eighth gap, on the eleventh gap unexpectedly, one among their arms began to tremble as their signs got here again with their OFF interval. Their sport simply — they began slicing and hooking each shot. It wasn’t a extreme OFF essentially. They weren’t incapacitated however their total outing grew to become embarrassing and depressing. And after a few these instances, these are actual tales that we have heard after a few instances of that occuring, the particular person the following time their buddy’s name and say, “Hey, tea time, Joe, on Saturday morning, 9:00.” They are saying, “Hey, you recognize what, you guys go on with out me as we speak. I am not feeling nicely.”
They start to isolate themselves, not as a result of they’re having an OFF in that second, however as a result of they’ve had them earlier than in embarrassing horrible conditions and now they’re afraid it may occur once more, they usually haven’t any approach of coping with it. Whereas if they’ve a approach of coping with it, they’ve an on-demand remedy you’ll be able to see what that might add to their potential to deal with their illness and the problems of their illness. And that impacts care companions as nicely.
So if you concentrate on this is an actual instance, we’ve one affected person who’s spouse is — he was once a Coast Guard pilot. His spouse is a salesman, and her job requires her periodically to journey. She instructed us that it obtained to some extent together with his OFF durations the place she was afraid to really exit and do her job. Afraid to go as she was pondering that she might need to surrender her job as a result of she was afraid to go away him alone if he obtained into hassle with an OFF interval and could not do something about it. And now you’ll be able to see the influence of getting INBRIJA. This affected person occurs to be on INBRIJA, the place they each know that he can deal with it on the time it occurs and our knowledge present that the onset of motion is in as little as 10 minutes.
So our marketing campaign is encouraging physicians to consider how OFF ends in Parkinson’s sufferers, making their lives smaller and the way we have to encourage them and their care companions to take actions that may give them again some management over their lives. We have elevated our digital promotion of this new marketing campaign. And in This autumn relative to Q3 and we noticed a 145% enhance in returning web site guests and a 104% enhance in web site guests taking what we name high-value actions. Reminiscent of downloading a brochure or watching a video or registering to get extra data and by the way in which, to the extent you all have an curiosity, I encourage you to go to imbrija.com. Check out the affected person earlier than and after movies you will really see the one I simply talked about with Jimmy and his spouse, Christie as she helps him out of a chair together with his OFF interval. I discover them extraordinarily compelling. I consider you’ll as nicely. And extra to the purpose, we’ve heard from physicians, different well being care professionals and sufferers and their care suppliers that they discover them compelling.
Transferring to AMPYRA. AMPYRA web gross sales for the total yr 2022 have been $73 million. That was in step with our steerage of $68 million to $78 million and this was a 13.7% lower from 2021. Gross sales within the fourth quarter have been $19 million, a $16.6 million lower over This autumn 2021. Recall that we’ve mentioned all alongside that this may decline over time relative to generics.
Nonetheless, the speed of gross sales decline versus generics has been leveling off fairly a bit, and we count on it to proceed to average. And I will present you that within the subsequent slide. So right here, you see from the start of generic competitors in This autumn of 2018, there’s a leveling of the decline of gross sales by way of the tip of 2022. The slope continues to flatten by way of 2022 and for 2022 — excuse me, 2023, we count on AMPYRA web gross sales between $65 million and $70 million.
Subsequent slide, we venture that AMPYRA gross sales over the following 5 years will stabilize at roughly $60 million a yr or increased primarily based on these developments and one thing actually encouraging to notice about 200 docs wrote prescriptions for branded AMPYRA in 2022, who had not written because it went generic in 2018.
And also you would possibly ask your self, nicely, why and we consider that efficiency is as a result of approach we have been sustaining the model. To begin with, we elevated our area gross sales calls on MS specialists to make sure that they’re conscious of the assorted help packages that we’re persevering with to supply for the model, a lot of them thought as soon as we went generic, that we have been not supporting it. And we discovered that we have to get that phrase out as a result of there’s plenty of embedded doctor and affected person model loyalty that we constructed up once we had the exclusivity interval.
And we proceed to listen to from each the well being care professionals or well being care suppliers and sufferers that they worth the help that we have at all times supplied and are persevering with to supply. That features our first step program that provides the preliminary 2 months of AMPYRA free to commercially insured sufferers, co-pay mitigation in order that sufferers with business insurance coverage are paying not more than $10 a month out of pocket for the model, which is lower than often they’re paying for generics.
And in addition, we proceed to supply doctor and reimbursement help. Entry additionally has remained excessive for AMPYRA about 70% of lined lives can get entry to it by way of insurance coverage. And with that, I will flip the decision over to our CFO, Mike Gesser who will evaluate the financials with us. Mike?
Michael Gesser
Thanks, Ron. Good morning, everybody. Along with our U.S. income, we reported $2.9 million of INBRIJA ex-U.S. gross sales, $11.7 million of FAMPYRA royalties, $2.6 million in royalties for Neurelis and $500,000 from Asieris Pharma for the medical belongings we licensed to them.
Trying on the 2022 monetary efficiency, we achieved our steerage as introduced in the beginning of the yr for AMPYRA and adjusted OpEx. Adjusted OpEx, as you recognize, is analysis and improvement, gross sales and common administration and is down from 2021 by roughly $18 million.
Internet earnings enchancment was impacted by Alkermes Award and the extinguishment of the Biotie Finland debt. We ended off the yr in a powerful money place. For 2023, we count on INBRIJA U.S. web income between $38 million and $42 million and a pure U.S. web income between $65 million and $70 million. We count on adjusted working bills of between $93 million and $103 million and we count on our ending money steadiness to be between $43 million and $47 million. And we plan on reaching a web impartial money circulation for the yr or higher. Extra steerage may be present in our long-term monetary steerage within the earnings launch. And now I will flip the decision again over to Ron.
Ron Cohen
Thanks, Mike. So reviewing our priorities, we’re persevering with to construct shareholder worth in 2023. At first, accelerating INBRIJA’s trajectory within the U.S., profiting from the brand new post-COVID setting with the business packages that I mentioned earlier and likewise closing new ex-U.S. offers, whereas our current offers proceed to roll out business launches in extra nations.
For instance, Biopas, our Latin American accomplice believes that they’re going to start to roll out launches in early 2024. And we’re negotiating extra offers or discussing extra offers for different territories on this planet proper now. Sustaining AMPYRA additionally stays an vital focus as we’ll proceed to tell the MS well being care suppliers in regards to the varied packages that we offer to help the product on behalf of MS sufferers. And we’re additionally, as you simply heard from Mike, decreasing working bills additional in 2023 over 2022 by between $9 million and $19 million, and that follows a complete of $64 million in reductions that we have already made between 2020 and 2022.
And as you heard, we count on to be money circulation impartial to constructive in 2023 and we’re persevering with to guage collaborations for creating vital new inhale therapies with our ARCUS know-how. And with that, we’ll thanks on your consideration, and we are going to open the decision for questions. Operator?
Query-and-Reply Session
Operator
We have now a query on the road from Boobalan Pachaiyappan with HC Wainwright.
Boobalan Pachaiyappan
That is Boobalan. Are you able to hear me okay?
Ron Cohen
Sure, we will.
Boobalan Pachaiyappan
I am dialing in for Ram Selvaraju. So firstly, how a lot are you spending on business prices for AMPYRA particularly?
Ron Cohen
You understand what, I do not consider we get away these numbers. However Mike, do you need to take that?
Michael Gesser
Nicely, we do not break these numbers out. So addressing that might most likely be a — we have to focus on how we need to craft that. However I’ll say, as we answered a query just like this prior to now, we do present direct gross sales and advertising and marketing help to AMPYRA by way of our gross sales drive.
We offer plenty of digital advertising and marketing and the conventional sorts of promoting and help that approach for AMPYRA. So and INBRIJA. It isn’t — it seems particularly, as Ron was saying, is just not a forgotten product, and we discover that the extra consideration we pay to AMPYRA by way of our gross sales and advertising and marketing and approaches returns relatively nicely to us for that effort, the docs reply positively.
Boobalan Pachaiyappan
Okay. And secondly, what do you count on peak gross sales of in INBRIJA to be in Europe? And the way does the pricing examine between the U.S. and European territories?
Ron Cohen
Sure. So once more, we aren’t at the moment giving steerage for European gross sales. To begin with, plenty of that relies on which nations get rolled out and when after which every nation has a special pricing scheme relying. So we’re not at the moment comfy that we can provide steerage on that. This actually relies on our companions and their ongoing evaluation of the market. I might say that normally, given our personal expertise right here, it takes some time to get a way of what is going on on out there and how one can venture so at this level, we simply do not feel that we may be correct sufficient in projections that we can provide them.
If we get to some extent if and once we get to some extent the place we will, we clearly will do this. By the way in which, I do need to make one correction whereas I am nonetheless pondering of it. I am instructed that I misspoke after I was presenting the slide on 2023 INBRIJA U.S. gross sales projections, I am unsure I mentioned the suitable vary, however the appropriate vary is $38 million to $42 million, $38 million and $42 million within the U.S. for 2023. So I simply need to be certain I corrected that, and let me return to your questions.
Boobalan Pachaiyappan
All proper. After which thirdly, how ought to we take into consideration value reducing and working expense management over the rest of 2023 and do you see any state of affairs by which additional value management can be required in 2024?
Ron Cohen
Mike, do you need to take that please.
Michael Gesser
Sure. So we’re persevering with to considerably scale back our working bills. We have now that plan for ’23 as we simply mentioned. And in case you return and take a look at our steerage — long-term steerage that we supplied in December, you will see that we do have a relatively tight management on working bills, not rising considerably as our income grows within the outlying years. we aren’t essentially planning on different important decreases as we really feel like we’re driving down our working bills to some extent that may help the gross sales that we’ve given steerage on sooner or later.
However we do take a look at each alternative and what you do not see, however you — is that we’re exchanging sure value departments for value and different. So there could be web reductions in sure departments, however these are used to fund different actions and departments that want extra funding are extra helpful to — that spend is extra helpful to the corporate.
Boobalan Pachaiyappan
Okay. After which one ultimate query from us. What are your plans for refinancing your convertible debt? And what sort of debt instrument would you contemplate most fascinating to interchange the prevailing facility?
Ron Cohen
Sure. So we clearly have the debt and we have to deal with it. What we will say, we won’t offer you specifics at this level however what we will say is that we keep in communication with the nice majority of our bondholders, that means the nice majority who personal the nice majority of debt. Luckily, it is pretty concentrated. There are possibly 8 or so holders who’re accounting for over 80% of the debt so we’re capable of have constructive conversations concerning the debt.
And we, the management staff and the Board are in actual time. We’re persevering with to guage varied methods of coping with the debt in hopefully, in collaboration with the bondholders. And when we’ve a call or choices on which approach we will go along with that, we will definitely let everybody know.
Operator
I’ll now flip the decision again to Tierney Saccavino, for additional remarks.
Tierney Saccavino
Thanks, Emily. So we do have a number of traders who’ve written in questions as they registered and I will learn them now. The primary query is, if the inventory value goes above $1 for 10 days, and your organization is again in compliance with NASDAQ itemizing guidelines, how will you announce that?
Ron Cohen
Nicely, we will surely — sure, we will surely announce it publicly that might be a cloth occasion. And as with all materials occasions, we might put that out very seemingly, I might assume, within the press launch.
Tierney Saccavino
Okay. Subsequent query. In case you’re assured about your long-term marketing strategy, we might count on to see Acorda insiders buying inventory. Do firm leaders or administrators have plans to take action?
Ron Cohen
So I can not speculate on that, however what I can say is that we’ve heard these issues from our shareholders and I’ve to say I am personally delicate to it, and we’re all delicate to it right here on the Board and the management staff. I might be aware that previously, the corporate management staff members, together with me, have bought our inventory.
This was clearly at increased costs earlier than. So we’re taking that underneath advisement, however we won’t make any advance or proactive bulletins about that. I hope you’ll be able to all admire. The opposite factor to grasp is that the Boards and management groups are fairly often constrained by possessing materials nonpublic data at any given time that limits how we will purchase or promote the inventory within the firm. And as you’ll be able to admire, in case you simply take a look at the final 6 months, for example, and all the issues that we introduced that we had beforehand been engaged on, you will get a way that particularly as we’re working to construct again the worth of the corporate and interesting in every kind of initiatives, it is extremely seemingly that at any given time, we could also be in possession of that data.
So Once more, we’re delicate to it. We have now achieved it earlier than. We have now purchased our inventory earlier than. I’ve purchased massive quantities of our inventory earlier than, and we are going to take all of that into consideration.
Tierney Saccavino
Okay. Subsequent query. Will you proceed to make your debt curiosity funds with money.
Ron Cohen
So — nicely, a few issues value noting. To begin with, there’s just one extra cost left on the upcoming June cost, the place we even have the choice to pay it in inventory that is just below the settlement with the bondholders. So that might be the one one the place there would even be an choice to not pay it in money. The Board usually makes that willpower about what we will do shortly earlier than the funds are due.
So I haven’t got a selected reply for you. However I can inform you that normally, as shareholders ourselves we’re very delicate to the dilution points which might be concerned. And our choice is to pay in money if we consider that’s in the perfect curiosity, taking all components into consideration. I feel it is also value noting if it offers you some consolation that we at the moment would not have practically sufficient shares to pay this June cost in shares at something near the present inventory value.
So hopefully, that gives you some sense of the reply. And as we get nearer, clearly, we’ll announce it. However our total view is that it’s typically talking, preferable to paying money except there are different compelling components that dictate in any other case.
Tierney Saccavino
Okay. Subsequent query. It seems that a shareholder or shareholders are promoting inventory each time the Acorda inventory goes above a $1 and possibly with the intention to maintain the value depressed. What’s your plan to deal with this?
Ron Cohen
So we — such as you, we monitor the inventory exercise carefully to search for any untoward patterns. I’ve to say that we’ve been involved about the kind of sample that you just simply articulated to the extent that we see exercise and might discover adequate proof for exercise that’s unethical or exterior the laws or unlawful we might instantly report that to the related authorities.
Tierney Saccavino
Okay. Subsequent query concerning Alkermes. What do you assume is the chance of having the ability to get clawbacks of extra royalties already paid along with your present authorized petition?
Ron Cohen
Nicely, we’re not capable of touch upon or speculate on ongoing litigation. The submitting is public. As you recognize, if the submitting signifies that we consider that we’re owed a further $65 million. That is going to be within the arms of the courtroom when we’ve our listening to, so please keep tuned for that.
Tierney Saccavino
Our subsequent query regarding INBRIJA with an absence of COVID over the past calendar yr, why are we nonetheless not seeing extra sturdy development?
Ron Cohen
So to begin with, we’ve not had an absence of COVID over the past calendar yr. In case you return, we had a surge final summer season. We had one other surge within the fall. So I might say it has been extra like roughly 6 months or much less, the place the nation has actually opened as much as an extent and significantly our a part of the nation, which is the physicians, the sufferers there — by the way in which, stroll into plenty of hospitals and docs’ workplaces as we speak, they’re nonetheless all requiring masks.
So it is not like everybody has already moved fully previous it. What we’re indicating is that over the past — let’s name it, 1 to 2 quarters, there’s been sufficient opening up and return to extra regular patterns of habits and medical exercise that we really feel, for the primary time within the pandemic that we’ve the type of opening we want.
And in addition perceive this isn’t like turning on a lightweight change. It is not like everybody strikes previous it to as we speak. After which unexpectedly, we’ve this main burst of prescriptions. No. It is virtually like relaunching in some respects, the place you simply should do the groundwork, you must get in entrance of them. It’s a must to get the brand new marketing campaign on the market.
The opposite new issues that we’ve carried out, for instance, the flexibility to e-prescribe which has been taken up very properly and really quickly by many of the prescribers at this level. The flexibility to purchase the product for money for lower than the co-pay for sufferers who can’t afford their co-pay on Medicare, for instance. So all of those packages that we’ve been setting up, you’ll be able to see, we put the brand new digital packages into place within the fourth quarter. And as I reported to you, we have already seen a 145% enhance in guests coming again versus the third quarter.
We have seen over 100% enhance in guests taking high-value actions once they come again. So all of that’s extraordinarily encouraging. And as I indicated, we have already seen considerably increased prescription exercise within the first 2 months of this yr versus final yr.
So we consider it’s taking maintain, nevertheless it’s simply going to take a while. And our integration of all that’s mirrored in our projection that we have given for INBRIJA for this yr of between I do not need to get it fallacious once more. It is between $38 million and $42 million for the yr.
Tierney Saccavino
The subsequent query is, was there a delay within the launch of INBRIJA in Spain.
Ron Cohen
No. No. Really, we have been happy that, that was proper on schedule. We have been telegraphing for a lot of final yr that we anticipated it to launch in Spain primarily based on Esteve’s timetable in early 2023. And actually, they launched in February. So I feel that qualifies as early 2023. We didn’t announce it till lately as a result of we needed to watch for Esteve to announce it in Spain. And once they introduced it, we introduced it, which was lately.
Tierney Saccavino
Subsequent query, is the corporate on monitor to ship on the long-term monetary outcomes outlined final yr?
Michael Gesser
I will take this, Ron.
Ron Cohen
Sure, please, Mike.
Michael Gesser
Sure. So our long-term steerage is included within the earnings launch. You will discover that it is basically the identical because the long-term steerage we launched in December for INBRIJA and AMPYRA gross sales and the one changes we have made to the opposite merchandise is a results of the catalyst restructuring the Catalent deal that we have lately concluded. So we are going to proceed to observe the efficiency carefully, and we are going to reiterate our steerage or any adjustments in steerage as acceptable.
Tierney Saccavino
Thanks. Subsequent query, why are you not capable of be money circulation impartial in 2022?
Michael Gesser
Ron, I will do that one additionally, please. I hoped we have been going to get this query. As we have been speaking about, the Omicron influence in Q1 considerably impacted INBRIJA income and it impacted it for the yr. That discount in income adversely affected our money circulation place as a result of we have been simply not receiving the income we anticipated and subsequently, the funds for the gross sales of our product. That’s the actual cause that we had so far as not getting money circulation impartial in This autumn. After we had talked about that previously, we had talked in regards to the quarter, the fourth quarter being money circulation impartial. We had made important reductions in our working bills as we had described. We did meet that steerage for working bills nicely as assembly our steerage for AMPYRA. And we really feel like we have ended the yr in a relatively sturdy money place for us and we’re persevering with to reiterate the steerage that we’re aiming to be money circulation impartial or a minimum of or constructive for the yr of 2023.
So we really feel fairly good about the place we’re given the immense maintain that we’ve been describing now for 4 quarters that we have been confronted with in Q1.
Tierney Saccavino
Thanks, Mike. Okay. The final writing query is, first, let me congratulate the staff and the administration for the nice work you’re doing. I want to see extra updates and information with regard to your operations. And possibly it is time to speak about a buyback or conversion of the convertibles shares for shares and that would go away the corporate with nice numbers and no debt.
Ron Cohen
Nicely, thanks for the present suggestions. We’re happy total with the efficiency this yr and — excuse me final yr, and what we’re seeing early this yr and the milestones that we have been capable of hit. We do announce information promptly every time we’ve a cloth replace within the firm, we made fairly quite a few these bulletins as I indicated within the final a number of months. We’re aiming to have extra to make this yr. As I discussed earlier, with respect to the bonds, we’re in contact with the bondholders. We’re persevering with to guage alternative ways of addressing the debt. And when we’ve a approach that we’ve settled on, we’re definitely going to announce that promptly.
Tierney Saccavino
Proper. That’s the finish of the writing query. So Ron, I will flip it again over to you.
Ron Cohen
All proper. Nicely, thanks, Tierney. Thanks, everybody, for becoming a member of us, and we look ahead to our subsequent replace. And those after that, we’re aiming to proceed what we have been doing for the final 6 months or so by way of producing constructive information and shareholder worth. Speak with you subsequent time. Thanks.
Operator
This concludes Acorda Therapeutics Fourth Quarter and 12 months Finish 2022 Monetary and Enterprise Replace. Thanks on your participation.
